3′-ethynylcytidine derivative

Details 3′-ethynylcytidine derivative 3′-ethynylcytidine derivative

2007-07-23

2011-11-15

Lewis, Patrick (Department: 1623)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

C514S043000, C536S028100, C536S028400

Reexamination Certificate

active

08058261

ABSTRACT:
To provide a compound which exhibits excellent anti-tumor activity and excellent oral absorption and which is a useful anti-tumor drug.The invention provides a 3′-ethynylcytidine derivative represented by formula (1):(wherein X represents a (substituted) alkylcarbonyl group, a (substituted) alkoxycarbonyl group, or a hydrogen atom; one of Y and Z represents a hydrogen atom or a group represented by (R1)(R2)(R3)Si— and the other represents a group represented by (R4)(R5)(R6)Si—; and R1, R2, R3, R4, R5, and R6each represent a (substituted) alkyl group, a (substituted) cyclic alkyl group, or a (substituted) aryl group) or a salt thereof.

REFERENCES:
patent: 5061793 (1991-10-01), Grindey et al.
patent: 5464826 (1995-11-01), Grindey et al.
patent: 5763418 (1998-06-01), Matsuda et al.
patent: 61-148193 (1986-07-01), None
patent: 10 298194 (1998-11-01), None
patent: 96 18636 (1996-06-01), None
Nowak et al. J. Org. Chem. (2005), vol. 70, pp. 7455-7458.
Robins et al. Can. J. Chem. (1981), vol. 59, pp. 2608-2611.
Hattori, H. et al., “Nucleosides and Nucleotides. 175. Structural Requirements of the Sugar Moiety for the Antitumor Activities of New Nucleoside Antimetabolites, 1-(3-C-Ethyny1-β-D-ribo-pentofuranosy1)cytosine and-uracil1”, Journal of Medicinal Chemistry, vol. 41, No. 15, pp. 2892-2902, (1998).
Hattori, H. et al. “Nucleosides and Nucleotides. 158. 1-(3-C-Ethyny1-β- D-ribo pentofuranosy1)-cytosine, 1-(3-C-Ethynyl-β-D-ribo-pentofuranosyl)uracil, and Their Nucleobase Analogues as New Potential Multifunctional Antitumor Nucleosides with a Broad Spectrum of Activity1”, Journal of Medicinal Chemistry, vol. 39, No. 25, pp. 5005-5011, (1996).
Nomura, M. et al., “Nucleosides and nucleotides. Part 212: Practical large-scale synthesis of 1-(3-C-ethynyl-β-D-ribo-pentofuranosyl)cytosine (ECyd), a potent antitumor nucleoside. Isobutyryloxy group as an efficient anomeric leaving group in the Vorbrueggen glycosylation reaction”, Tetrahedron, vol. 58, No. 7, pp. 1279-1288, (2002).
John S. Evans, et al., “Antitumor Activity of 1-β-D-Arabinofuranosylcytosine Hydrochloride”, Proc. Soc. Exp. Bio. Med., vol. 106, 1961, pp. 350-353.
Akio Hoshi, et al., “Antitumor Activity of 1-Hexylcarbamoyl-5-Fluorouracil in a Variety of Experimental Tumors”, Gann, vol. 67, No. 5, Oct. 1976, pp. 725-731.
Satoshi Tabata, et al., “Antitumor effect of a novel multifunctional antitumor nucleoside, 3′-ethynylcytidine, on human cancers”, Oncology Reports, vol. 3, 1996, pp. 1029-1034.
Motohiro Tanaka, et al., Cancer & Chemotherapy, vol. 24-4, 1997, pp. 476-482.
Peter S. Ludwig, et al., “A New Laboratory Scale Synthesis for the Anticancer Drug 3′-C-Ethynylcytidine”, Synthesis, No. 16, 2002, pp. 2387-2392.

Affiliated with

Also associated with

Rating

3′-ethynylcytidine derivative does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with 3′-ethynylcytidine derivative, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 3′-ethynylcytidine derivative will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4293515